Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

abstract：:Investigators representing all major melanoma research areas present an overview of the most important challenges for the field. Four major research areas are covered plus the training of new investigators. For each area we first describe the present status, its strengths and weaknesses, and then outline specific reco...

journal_title：Seminars in oncology

authors： Herlyn M,Halaban R,Ronai Z,Schuchter L,Berwick M,Pinkel D

更新日期：2007-12-01 00:00:00

abstract：:In spite of the chemosensitivity seen with the initial treatment of malignant lymphoid disorders, relapse is common and death most often occurs as a result of disease progression. This is related to a multitude of resistance mechanisms associated with the various lymphoproliferative disorders. As a result, therapies t...

journal_title：Seminars in oncology

authors： Byrd JC,Grever MR,Waselenko JK,Willis CR,Park K,Goodrich A,Lucas MA,Shinn C,Flinn IW

更新日期：2000-04-01 00:00:00

abstract：:Over the past three decades conceptual approaches to breast cancer have led to improvements in locoregional therapy and early diagnosis. Systematic screening programs with mammography reduce disease-specific mortality by 25% to 30%, while many patients with early breast cancer receive optimal breast-conserving treatme...

journal_title：Seminars in oncology

authors： Hortobagyi GN,Hung MC,Buzdar AU

更新日期：1999-08-01 00:00:00

abstract：:Patients with successfully treated upper aerodigestive tract (UADT) tumors commonly develop second primary tumors (SPTs). These tumors occur more often than chance would predict, arise in both the upper or lower aerodigestive tracts, are frequently preceded by leukoplakia, and are a major cause of treatment-related fa...

journal_title：Seminars in oncology

authors： Anderson WF,Hawk E,Berg CD

更新日期：2001-02-01 00:00:00

abstract：:During the past decade, local control of primary sarcomas of the extremities by radiation and conservative surgery has supplanted more radical compartmental resections or amputations. Reviews of others and our published data show that the probability of achieving local control is highly dependent on achieving negative...

journal_title：Seminars in oncology

authors： Spiro IJ,Gebhardt MC,Jennings LC,Mankin HJ,Harmon DC,Suit HD

更新日期：1997-10-01 00:00:00

abstract：:Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

journal_title：Seminars in oncology

authors： Coleman RE,Seaman JJ

更新日期：2001-04-01 00:00:00

abstract：:The American Joint Committee on Cancer (AJCC) recently launched a new staging system for cutaneous melanoma that was based on clinical experience with a large number of patients treated in major centers worldwide. As this system includes various histopathologic parameters of the primary melanoma and of melanoma metast...

journal_title：Seminars in oncology

authors： Ruiter DJ,Spatz A,van den Oord JJ,Cook MG,Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group.

更新日期：2002-08-01 00:00:00

abstract：:Hypercalcemia, a complication that develops in 10% to 20% of patients with cancer, results from disruption of the normal physiologic mechanisms that closely regulate calcium homeostasis. Most patients with hypercalcemia are seriously dehydrated, and this volume depletion further compromises the kidney's ability to exc...

journal_title：Seminars in oncology

authors： Ritch PS

更新日期：1990-04-01 00:00:00

abstract：:In geographic areas where there is a high risk of esophageal cancer, analysis of cells obtained from the esophagus has been used effectively to detect early lesions. This has been demonstrated on a large scale in studies from China. Using abrasive balloon cytology techniques, 75% of the cancers detected were early les...

journal_title：Seminars in oncology

authors： Lightdale CJ,Winawer SJ

更新日期：1984-06-01 00:00:00

abstract：:Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant c...

journal_title：Seminars in oncology

authors： Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

更新日期：1988-02-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the United States. Despite evidence of molecular abnormalities in biological specimens, progress in this disease is hampered by the lack of diagnostic markers useful for clinical practice. The majority of patients with lung cancer are still diagnosed at an advanced s...

journal_title：Seminars in oncology

authors： Wardwell NR,Massion PP

更新日期：2005-06-01 00:00:00

abstract：:Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a deta...

journal_title：Seminars in oncology

authors： Fonseca R,Monge J

更新日期：2013-10-01 00:00:00

abstract：:Metastatic germ cell cancer is a very heterogeneous group with respect to prognosis under cisplatinum-based chemotherapy. The main determinants of complete response and survival are not only the extension of the metastases but much more the biology of the underlying tumor which is represented by the location of the me...

journal_title：Seminars in oncology

authors： Schmoll HJ,Beyer J

更新日期：1998-04-01 00:00:00

abstract：:Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article review...

journal_title：Seminars in oncology

authors： Schuchter LM,Luginbuhl WE,Meropol NJ

更新日期：1992-12-01 00:00:00

abstract：:The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 with the newer drugs have improved the overall survival compared to retrospective historical data an...

journal_title：Seminars in oncology

authors： Greco FA,Pavlidis N

更新日期：2009-02-01 00:00:00

abstract：:Recent data indicate that cellular immune responses can produce an anticancer effect. Two types of cellular immune responses appear to be clinically relevant: antigen specific immunity mediated by T cells that recognize tumor-associated peptide antigen expressed on surface HLA class I or class II molecules, and antige...

journal_title：Seminars in oncology

authors： Waller EK

更新日期：2004-04-01 00:00:00

abstract：:Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

journal_title：Seminars in oncology

authors： Arteaga CL,Khuri F,Krystal G,Sebti S

更新日期：2002-02-01 00:00:00

abstract：:As a result of the increasing effectiveness of cancer screening and preventive interventions, ethical issues, as well as legal liabilities, are increasingly associated with cancer genetic testing. These issues include the possible "duty to warn" relatives of inherited cancer risk, the appropriateness of testing of chi...

journal_title：Seminars in oncology

authors： Offit K,Thom P

更新日期：2007-10-01 00:00:00

abstract：:The combination of paclitaxel and carboplatin is now established as the standard first-line chemotherapy regimen for advanced ovarian cancer. Ways in which this standard therapy can be further improved are being investigated, and several approaches have been taken. One approach is to integrate a different cytotoxic ag...

journal_title：Seminars in oncology

authors： Thigpen T

更新日期：2006-04-01 00:00:00

abstract：:Initial phase I trials of intraperitoneal chemotherapy in ovarian cancer patients demonstrated that a pharmacologic advantage was achieved with the direct instillation of drugs into the peritoneal cavity. Recent trials have reported that approximately 30% of patients who have small-volume residual disease following in...

journal_title：Seminars in oncology

authors： Ozols R

更新日期：1985-09-01 00:00:00

abstract：:Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

journal_title：Seminars in oncology

authors： Dalakas MC,Mock V,Hawkins MJ

更新日期：1998-02-01 00:00:00

abstract：:Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful. Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurri...

journal_title：Seminars in oncology

authors： Falardeau P,Champagne P,Poyet P,Hariton C,Dupont E

更新日期：2001-12-01 00:00:00

abstract：:Fludara I.V. (fludarabine phosphate) (9-beta-D-arabinosyl-2-fluoroadenine, F-ara-A) is an adenine nucleoside analogue resistant to adenosine deaminase that shows promising therapeutic activity in the clinical treatment of lymphocytic hematologic malignancies. F-ara-A is transported into cells, where it is converted to...

journal_title：Seminars in oncology

authors： Plunkett W,Huang P,Gandhi V

更新日期：1990-10-01 00:00:00

abstract：:Despite marked improvements in the treatment options available for patients with lung cancers, more than 85% of patients ultimately relapse and die of their disease. Among the most auspicious of new agents available to treat lung cancers, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) also has been th...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1996-12-01 00:00:00

abstract：:Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have b...

journal_title：Seminars in oncology

authors： Hiddemann W,Dreyling M,Unterhalt M

更新日期：2003-02-01 00:00:00

abstract：:A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

journal_title：Seminars in oncology

authors： Ettinger DS

更新日期：2005-04-01 00:00:00

abstract：:Data from various phase I/II studies of carboplatin in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) have suggested that the degree of thrombocytopenia seen is less than that expected when carboplatin is given alone. However, some studies also have suggested that the area under the p...

journal_title：Seminars in oncology

authors： Calvert AH,Boddy A,Bailey NP,Siddiqui N,Humphreys A,Hughes A,Robson L,Gumbrell L,Thomas H,Chapman F

更新日期：1995-10-01 00:00:00

abstract：:Colorectal cancer is the third most common cause of cancer-related death in both men and women. Surgery is the primary form of treatment, with greater than 90% of patients surviving 5 years or more. The remaining patients have metastatic disease, for which treatment options are limited. The fluoropyrimidine, 5-fluorou...

journal_title：Seminars in oncology

authors： Creemers GJ

更新日期：1997-12-01 00:00:00

abstract：:Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

journal_title：Seminars in oncology

authors： Zinzani PL

更新日期：2005-02-01 00:00:00

abstract：:The consistently high mortality rates associated with gastrointestinal cancer result in large part from malignancies that progress undetected to an advanced stage of disease when treatment is usually less effective. In response to this fact, increasing attention has been directed toward developing methods of both prim...

journal_title：Seminars in oncology

authors： Winawer SJ

更新日期：1991-02-01 00:00:00